Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5013214 | 1.00 | LMNA (0.46) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL3637756 | 1.00 | LMNA (0.46) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL2996166 | 0.85 | LMNA (0.48) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL25588104 | 0.84 | LMNA (0.44) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL19859189 | 0.83 | CA12 (0.46) | GRM4CA12CA1CA2CA9 | |
| SCHEMBL13896753 | 0.83 | MEN1 (0.43) | LMNAMEN1KMT2APTGS1 | |
| Hydrochloric Acid SCHEMBL19859289 | 0.82 | CA12 (0.44) | GRM4CA12CA1CA2CA9 | |
| SCHEMBL25588108 | 0.81 | LMNA (0.42) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL28558589 | 0.80 | CA12 (0.47) | LMNATSHRMEN1CYP3A4KMT2A | |
| SCHEMBL21914796 | 0.80 | CA12 (0.47) | LMNATSHRMEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894311-B | Preparation of ethyl (2S, 3R) -2-amino-3-hydroxy-3- (4- (methylsulfonyl) phenyl) propionate | 天津工微生物科技有限公司 | 2023-05-30 | — | — | CN | claimed |
| CN-116693432-B | Preparation method of florfenicol intermediate D-ethyl ester | 山东国邦药业有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116693432-A | Preparation method of florfenicol intermediate D-ethyl ester | 山东国邦药业有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20230183175-A1 | METHOD FOR PREPARING INTERMEDIATE FOR USE IN SYNTHESIS OF FLORFENICOL AND COMPOUNDS PREPARED THEREBY | HEADING NANJING PHARMTECHNOLOGIES CO LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183175-A1 | METHOD FOR PREPARING INTERMEDIATE FOR USE IN SYNTHESIS OF FLORFENICOL AND COMPOUNDS PREPARED THEREBY | HEADING NANJING PHARMTECHNOLOGIES CO LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| CN-115894311-B | Preparation of ethyl (2S, 3R) -2-amino-3-hydroxy-3- (4- (methylsulfonyl) phenyl) propionate | 天津工微生物科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115894311-B | Preparation of ethyl (2S, 3R) -2-amino-3-hydroxy-3- (4- (methylsulfonyl) phenyl) propionate | 天津工微生物科技有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20210198192-A1 | METHODS FOR PREPARING FLORFENIOL AND INTERMEDIATE THEREOF | HEADING (NANJING) PHARMTECHNOLOGIES CO., LTD. (CN) | 2021-07-01 | — | — | US | disclosed |
| CN-109928901-B | Synthetic method of florfenicol intermediate | 上海医药工业研究院 | 2020-12-11 | — | — | CN | disclosed |
| WO-2020238779-A1 | METHOD FOR SYNTHESIZING FLORFENICOL | 上海博璞诺科技发展有限公司 | 2020-12-03 | — | — | WO | disclosed |
| WO-2010014566-A2 | PROCESS FOR PREPARING OXAZOLINE-PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | INTERVET INTERNATIONAL B.V. (NL) | 2010-02-04 | — | — | WO | disclosed |
| EP-1934189-A2 | A PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | Schering-Plough Ltd. (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934190-A2 | AN IMPROVED PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | Schering-Plough Ltd. (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1928820-A2 | A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL | Schering-Plough Ltd. (CH) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007030385-A2 | A PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | SCHERING-PLOUGH LTD. (CH) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030405-A2 | A PROCESS FOR PREPARING ESTER OXAZOLIDINE COMPOUNDS AND THEIR CONVERSION TO FLORFENICOL | SCHERING-PLOUGH LTD. (CH) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030386-A2 | AN IMPROVED PROCESS FOR PREPARING OXAZOLIDINE PROTECTED AMINODIOL COMPOUNDS USEFUL AS INTERMEDIATES TO FLORFENICOL | SCHERING-PLOUGH LTD. (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20070055080-A1 | Process for preparing ester oxazolidine compounds and their conversion to Florfenicol | SCHERING-PLOUGH ANIMAL HEALTH CORP. | 2007-03-08 | — | — | US | disclosed |
| US-20070055066-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol | SCHERING-PLOUGH ANIMAL HEALTH CORP | 2007-03-08 | — | — | US | disclosed |
| US-20070055067-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to Florfenicol | SCHERING-PLOUGH ANIMAL HEALTH CORP. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055080-A1 | Process for preparing ester oxazolidine compounds and their conversion to Florfenicol | CYP4F8, CYP4F2, CYP2F1 | LMNA 1934/4885TSHR 3720/4885MEN1 1509/4885 |
| US-20070055067-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to Florfenicol | DHFR, DPYD, AMPD2 | LMNA 1668/4885TSHR 4433/4885MEN1 1783/4885 |
| US-20070055066-A1 | Process for preparing oxazolidine protected aminodiol compounds useful as intermediates to florfenicol | DHFR, DPYD, AMPD2 | LMNA 1668/4885TSHR 4433/4885MEN1 1783/4885 |
| US-20230183175-A1 | METHOD FOR PREPARING INTERMEDIATE FOR USE IN SYNTHESIS OF FLORFENICOL AND COMPOUNDS PREPARED THEREBY | CYP4F2, CYP4F3, CYP2F1 | LMNA 3718/4885TSHR 4697/4885MEN1 1428/4885 |
| US-20210198192-A1 | METHODS FOR PREPARING FLORFENIOL AND INTERMEDIATE THEREOF | CYP4F3, CYP4F11, CYP2F1 | LMNA 1334/4885TSHR 2477/4885MEN1 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.